Blue Sail Medical Co.,Ltd. (SZSE:002382) agreed to acquire CB Cardio Holdings V Limited from Beijing Zhongxin Investment Center (Limited Partnership) for CNY 2.1 billion on December 18, 2017. Blue Sail Medical Co.,Ltd signed an agreement with Beijing Zhongxin Investment Center (Limited Partnership) on December 22, 2017. Under the terms, Blue Sail Medical Co.,Ltd will acquire 49.82 million shares by issue 187.4 million shares as consideration shares at CNY 10.95 per share. As on March 22, 2018, the deal terms revised. As per the new consideration details, 190.9 million new shares will be issued at revised offer price. In related deal, Blue Sail Medical Co.,Ltd. also agreed to acquire Cardio Holdings II Limited. Through the acquisition of CB Cardio Holdings V Limited, Blue Sail Medical Co.,Ltd. will also indirectly own 30.76% stake in CB Cardio Holdings II Limited. For the year ended December 31, 2016, CB Cardio Holdings V Limited reported total assets of CNY 567.6 million, net loss of CNY 33.8 million and net assets of CNY 291.4 million. The deal is subject to approval from shareholders of Blue Sail Medical Co.,Ltd. and China Securities Regulatory Commission. On December 18, 2017, the Board of Directors of CB Cardio Holdings V Limited made a resolution and approved to transfer the shares to Blue Sail Medical Co.,Ltd. On December 22, 2017, the Board of Directors of Blue Sail Medical Co.,Ltd. approved the deal. As of December 22, 2017, Beijing Zhongxin Investment Center (Limited Partnership) has all completed their respective internal decision-making procedures in related to the transaction. On January 8, 2018, the deal was approved by shareholders of Blue Sail Medical Co.,Ltd. On January 23, 2018, the Ministry of Commerce issued the notice of “Anti-Monopoly Bureau’s decision of not implementing further examination” as per which it decided not to implement further examination to this transaction. On March 15, 2018, the Department of Commerce of Shandong Province issued the certificate of enterprise’s overseas investment, approving this transaction. On March 28, 2018, the transaction was approved by the China Securities Regulatory Commission. On May 10, 2018, the Securities Regulatory Commission approved to issue consideration shares. Geng Lisheng, Zhong Shuqiao, Jin Mengmeng, Wang Tianshu, Chen Yudong and Tian Yuji of Morgan Stanley Huaxin Securities Company Limited acted as financial advisors and Xue Li and Wang Heng of Fangda Partners acted as legal advisors for Blue Sail Medical Co.,Ltd. Ma Tianyu, Ren Liguang, Liang Jieyan and Wang Xin of King & Wood Mallesons acted as legal advisors for Morgan Stanley Huaxin Securities Co., Ltd. Xie Yanfeng, Shen Han and Wang Jue of Deloitte Touche Tohmatsu Certified Public Accountants LLP acted as accountants for CB Cardio Holdings V Limited.